Skandinaviska Enskilda Banken (SEB)
RLMD icon

Skandinaviska Enskilda Banken (SEB)’s Relmada Therapeutics RLMD Stock Holding History

Skandinaviska Enskilda Banken (SEB)’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,984
Closed -$740K – 903
2022
Q3 		$740K Hold
19,984
– – 0.01% 720
2022
Q2 		$379K Buy
+19,984
New +$436K ﹤0.01% 842

Other funds holding RLMD

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
PCM
Parsons Capital Management Providence, Rhode Island $2.21B AUM 28.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Skandinaviska Enskilda Banken (SEB)'s RLMD Position: Q4 2022 in Review

Skandinaviska Enskilda Banken (SEB) sold out of Relmada Therapeutics (RLMD) in Q4 2022, closing a stake of 19,984 shares — an estimated $740K sold.

Skandinaviska Enskilda Banken (SEB) first reported a position in RLMD in Q2 2022 and held it in 2 quarters. The position peaked at $740K in Q3 2022. 110 funds tracked by Wall St. Rank hold RLMD as of Q4 2022.

  • Skandinaviska Enskilda Banken (SEB) reported no remaining Relmada Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Skandinaviska Enskilda Banken (SEB) sold 19,984 Relmada Therapeutics shares in Q4 2022, an estimated $740K.
  • Skandinaviska Enskilda Banken (SEB) first reported a position in Relmada Therapeutics in Q2 2022 and held it in 2 quarters.
  • Skandinaviska Enskilda Banken (SEB)'s Relmada Therapeutics position peaked at $740K in Q3 2022.
  • 110 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2022.

Based on Skandinaviska Enskilda Banken (SEB)'s 13F filing for Q4 2022, filed 8 Feb 2023.